OpenEvidence hits $12B valuation as specialized medical AI demand doubles in months

In just three months, its market value has doubled. Medical AI powerhouse OpenEvidence has reached a staggering $12 billion valuation, proving that Silicon Valley is placing its biggest bets on deep, vertical expertise rather than broad, general-purpose AI.

OpenEvidence hits $12B valuation via Series D milestone

According to TechCrunch, OpenEvidence announced on Wednesday that it's raised $250 million in a Series D funding round co-led by Thrive Capital and DST. This new injection of capital values the startup at $12 billion, a 100% jump from its $6 billion valuation in October 2025. The company has now raised a total of $700 million to date.

Surpassing $100M in revenue through clinician trust

While many AI startups struggle with monetization, OpenEvidence has already surpassed the $100 million revenue mark. Its platform served 18 million clinical consultations from verified U.S. healthcare professionals in December 2025 alone—a massive spike from the 3 million monthly searches recorded just a year prior.

Winning the healthcare AI war against giants

Investors don't seem worried about competition from OpenAI or Anthropic. OpenEvidence's laser focus on doctor-facing clinical information sets it apart from Anthropic's broader 'Claude for Healthcare' and ChatGPT's consumer-centric health products. The startup's ability to win over skeptical medical professionals gives it a moat that general models haven't yet breached.